meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
versus all
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab plus platin plus 5FU
All patients
Age < 65y (younger)
Age > 65y
cancer type (metastatic)
cancer type (recurrent)
ECOG 0
ECOG 1
Gender, female
Gender, male
P16 negative (HPV)
P16 positive (HPV)
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mHNSCC - L1 - PDL1 positive
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 1st line (L1)
mHNSCC - L1 - PDL1 positive
versus cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
2
certainty unassessable
statistically conclusive
-34%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open